515 related articles for article (PubMed ID: 34510295)
1. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
[TBL] [Abstract][Full Text] [Related]
2. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Helliwell P; Coates LC; FitzGerald O; Nash P; Soriano ER; Elaine Husni M; Hsu MA; Kanik KS; Hendrikx T; Wu J; Kudlacz E
Arthritis Res Ther; 2018 Oct; 20(1):242. PubMed ID: 30373651
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
Nash P; Coates LC; Fleischmann R; Papp KA; Gomez-Reino JJ; Kanik KS; Wang C; Wu J; Menon S; Hendrikx T; Ports WC
Rheumatol Ther; 2018 Dec; 5(2):567-582. PubMed ID: 30414064
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies.
Merola JF; Papp KA; Nash P; Gratacós J; Boehncke WH; Thaçi D; Graham D; Hsu MA; Wang C; Wu J; Young P
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2809-2820. PubMed ID: 32271970
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials.
Dai Q; Zhang Y; Liu Q; Zhang C
Clin Rheumatol; 2024 May; 43(5):1605-1613. PubMed ID: 38517652
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
[No Abstract] [Full Text] [Related]
8. Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies.
Mease PJ; Orbai AM; FitzGerald O; Bedaiwi M; Dona L Fleishaker ; Mundayat R; Young P; Helliwell PS
Arthritis Res Ther; 2023 Aug; 25(1):153. PubMed ID: 37608391
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Mease P; Hall S; FitzGerald O; van der Heijde D; Merola JF; Avila-Zapata F; Cieślak D; Graham D; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1537-1550. PubMed ID: 29045212
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies.
Ritchlin CT; Giles JT; Ogdie A; Gomez-Reino JJ; Helliwell P; Young P; Wang C; Wu J; Romero AB; Woolcott J; Stockert L
ACR Open Rheumatol; 2020 Oct; 2(10):543-554. PubMed ID: 32910531
[TBL] [Abstract][Full Text] [Related]
11. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.
Gladman DD; Coates LC; Wu J; Fallon L; Bacci ED; Cappelleri JC; Bushmakin AG; Helliwell PS
Arthritis Res Ther; 2022 Feb; 24(1):40. PubMed ID: 35139908
[TBL] [Abstract][Full Text] [Related]
12. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension.
Eder L; Gladman DD; Mease P; Pollock RA; Luna R; Aydin SZ; Ogdie A; Polachek A; Gruben D; Cadatal MJ; Kinch C; Strand V
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36958766
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.
Nash P; Mease PJ; Fleishaker D; Wu J; Coates LC; Behrens F; Gladman DD; Kivitz AJ; Wei JC; Shirinsky I; Menon S; Romero AB; Fallon L; Hsu MA; Wang C; Kanik KS
Lancet Rheumatol; 2021 Jan; 3(1):e28-e39. PubMed ID: 38273637
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib: A Review in Psoriatic Arthritis.
Paik J; Deeks ED
Drugs; 2019 Apr; 79(6):655-663. PubMed ID: 30895473
[TBL] [Abstract][Full Text] [Related]
17. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
Mulder MLM; Vriezekolk JE; den Broeder N; Mahler EAM; Helliwell PS; van den Hoogen FHJ; den Broeder AA; Wenink MH
Trials; 2020 Feb; 21(1):155. PubMed ID: 32041657
[TBL] [Abstract][Full Text] [Related]
18. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis.
Giles JT; Ogdie A; Gomez Reino JJ; Helliwell P; Germino R; Stockert L; Young P; Joseph W; Mundayat R; Graham D; Ritchlin C
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33452181
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Nash P; Coates LC; Kivitz AJ; Mease PJ; Gladman DD; Covarrubias-Cobos JA; FitzGerald O; Fleishaker D; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Romero AB; Kanik KS
Rheumatol Ther; 2020 Sep; 7(3):553-580. PubMed ID: 32506317
[TBL] [Abstract][Full Text] [Related]
20. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
